13^th European Diabetes and Endocrinology Congress November 26-27, 2018 Dublin, Ireland

Diabetes Therapeutics and Diagnostics

The incidence rate of diabetes is exceptionally high across the globe, fueled by reducing physical activities and unhealthy diet. According to IMARC’s report, compared to Type-1 diabetes, Type-2 diabetes represents the more prevalent type, accounting for the majority of all diagnosed diabetes cases. Urban areas dominate rural areas in the number of diabetes patients and females presently account for the majority of the total diabetes patients. Despite the general down climate of the economy and healthcare, there has been great progress in the advancement of diabetes knowledge, treatment and prevention in recent years. This progress continues of a daily basis, with scientific advances being announced at an exponential rate. New therapeutic products are being introduced regularly and the pipeline is now full of new diabetes therapeutics in development. Never before, in the history of medicine, has the outlook for diabetes treatment and prevention looked so promising. The diabetes drugs segment dominated the endocrinology drugs market and accounted for more than 86% of the market share during 2015. At an annual growth rate (CAGR) of 4.4%, from 2016 to 2021, World diabetes market projected to reach $155 billion by 2021 from $125 billion.

                                                    Fig: Global Diabetes Devices Market by Geography.

Endocrinology and Metabolism

The tracks discusses concerning the dire increase within the prevalence of assorted hormone-related medical conditions like diabetes, hypogonadism, hypothyroidism and hyperthyroidism. Interventions in medicine create an enormous impact on lifetime of patients with endocrine diseases. This endocrinology conference discusses the role vie by each medical and surgical interventions in practice of endocrinology. Endocrinology is branch of medication wherever treatment is as near ideal as doable. For people with endocrine deficiencies, medical intervention in form of replacement with hormones generated by recombinant technologies is a perfectly natural treatment. Hormone excess is additionally being evaluated and treated with passing precise surgical interventions with minimal morbidity. The global endocrinology market is poised to grow steadily at a CAGR of more than 6% over the forecast period, as per Technavio. The Global Endocrine Testing Market will grow strong during the forecast period 2017 to 2025. According to several analyses, nearly 415 million individuals were affected by diabetes in 2015 and this number is very likely to touch 642 million by 2040. 

                                                          Fig: Molecular Diagnostics Market Forecast.

Hormone Dependent Cancers

Hormones not just influence breast and glandular cancer (2 most common hormone-dependent cancers), however even have a serious impact on less common hormone-sensitive malignancies (e.g. ovary, testes, endometrium) additionally human cancers recently discovered to be hormone sensitive (e.g. lung, liver). Developing a way to more precisely treat and forestall hormone-dependent cancers is of essential importance given the significant impact these malignancies have on human health and also the economic burden of disease. An in depth understanding of hormone action in regulating diverse cellular processes, cancer phenotypes and drug responsiveness is essential for the development of effective and well tolerated treatment strategies. A recent advance in the field has been the understanding and exploitation of pathway cross-talk in hormone dependent cancer, which will also compose a part of the conference. Distribution of breast cancer therapeutics through retail pharmacies has become the most popular medium. In 2016, retail pharmacies held the largest market share and will grow at considerable rate over the forecast timeframe owing to increased number of pharmacies in both developed and developing regions. Breast Cancer Therapeutics Market is poised to cross USD 28 billion by 2024, as per the recent research.

                                                         Fig: Cancer Therapeutics Market Forecast.

Thyroid Disorders

Thyroid cancer is a metastatic tumor of the thyroid gland. It is comparatively uncommon compared to other cancers. Within USA, it is calculated that in 2016 close to 64,000 new patients will be diagnosed with thyroid cancer, compared to more than 240,000 patients with breast cancer and 135,000 patients with colorectal cancer. However, fewer than 2,000 patients die of thyroid cancer annually. In 2013 over 630,000 patients were living with thyroid cancer within USA. Recent epidemiological data from WHO suggests that there are more than 750 million cases globally with a thyroid disorder. Increasing focus by government organizations and private agencies like WHO and pharmaceutical companies, to create awareness of thyroid deficiency is fuelling the market growth. Levothyroxine and Cytomel are the most selling drugs in the thyroid deficiency treatment market.

                                           Fig: Thyroid Gland Disorders Treatment Market by Geography.

Adrenal Disorders

There are several diseases and dysfunctions related to the adrenal. One among them is the growth of tumors on the glands. These tumors are benign or cancerous and might throw off the proper production of hormones. A tumor that causes the gland to make an excessive amount of secretion is termed a functioning tumor, whereas a tumor that cause’s insufficient hormone secretion is termed a nonfunctioning tumor. Approximately 4 to 12 out of 1 million people develop a type of adrenal tumor called adrenocortical carcinoma, according to American Society of Clinical Oncology. Addison’s disease affects one hundred ten to one hundred forty four of every one million people in developed countries. Cushing's syndrome is uncommon which is affecting about 10 to 15 out of every 1 million people each year. CAH is one among the foremost common genetic disorders, poignant roughly 1 in 100 people, whereas mild CAH is much more common than severe CAH. Severe CAH is estimated to occur in 1 in 14,000 people. Although a large number of people have pituitary tumors (up to 20% of the world's population), most of these tumors are not cancerous, do not cause symptoms, and are never diagnosed.

                                                       Fig: Progressive responsibility the adrenal glands

Pituitary and Neuroendocrinology

With a prevalence of about 10% on MR imaging in the general population, Pituitary tumors are more common than typically thought.  At the same time, many endocrinologists and internists may not have sufficient exposure to deal confidently with a variety of pituitary disorders.  If not properly treated, pituitary disorders may result in significant morbidity and lower life expectancy.  The pituitary is the center of human sexuality and reproduction. Other parts of the body do most of the work but the pituitary initiates and controls the processes. Because of hormones about 30 and 40% of the population suffers sexual dysfunction at some time in their life. Endocrinology Society studies have reported that CDI is more prevalent in children and older adults (>80 years of age). Primary tumors of the pituitary fossa result in CDI in 50% of children and 30% of adults, while head trauma to the posterior pituitary gland accounts for 2% of cases in children and 17% in adults. Hypopituitarism is listed as a rare disorder by the National Institutes of health. To date, there are no US-based studies on the prevalence and incidence of hypopituitarism.  One published report indicated it affects less than 200,000 individuals in the US.  And the 2010 National Hospital Discharge Survey reported 17,101 US inpatient hospital visits with anhypopituitarism/ hypopituitarism) as one of any listed diagnoses, and 749 visits with this as the primary diagnosis. In addition, the reported average hospital stay was 5.4 days.

                                     Fig: Global Neuroendocrine Tumor Treatment Market Share, By Drug

Reproductive Endocrinology

It is estimated that globally 15% of couples affected by Infertility, amounting to 48.5 million couples. Males are found to be solely responsible for 20-30% of infertility cases and contribute to 50% of cases overall. The problem affects around one in seven couples in the U.K, which translates as approximately 3.5 million people. When the balance of many different hormones goes wrong at any point in the body, infertility is a potential result. There are several health conditions that are specific to the endocrine (hormonal) system of the body. Hormone imbalances are not solely a female fertility problem. Male fertility will reduce if there is a problem with testosterone levels among different hormones produced by the pituitary and thyroid glands. Female infertility will result from hormone problems, physiological problems and lifestyle or environmental factors. Infertility occurs in around 12% of women in the UK. In around thirty percent of patients the cause for hyperprolactinemia is not known.

                                                                Fig: Percentage Cause of Infertility

Osteoporosis and Bone Health

A healthy skeletal system with strong bones is crucial to quality and healthy life. But too many people suffer from bone disease and fractures, much of which could be prevented. An estimated ten million people in USA over age 50 have osteoporosis, while another 34 million are at risk. Every year around 1.5 million people suffer an osteoporotic-related fracture which causes downward spiral in physical and mental health. Nearly twenty percent of aged people who suffer a hip fracture die within a year. One out of every two women over 50 will have an osteoporosis-related fracture in their lifetime, with risk of fracture increasing with age. In USA, more than 53 million people either already possess osteoporosis or are at high risk due to low bone mass.

                                                           Fig: Effect of physical activity on bone mass

Endocrine Tumours and Neoplasia

It is estimated that over 12,000 Americans are diagnosed with an endocrine tumor every year. Over 1,500 people in the United States are diagnosed with Merkel cell skin cancer each year. Most of the people diagnosed with the disease are over age 50, and 90% of cases occur in white people. The 5-year survival rate of people with Merkel cell cancer is about 60%. MEN1 (Multiple endocrine neoplasia type 1) is a hereditary condition associated with tumors of the endocrine glands. MEN1 was originally known as Wermer syndrome. It is estimated that about 1 in 30,000 people has MEN1. According to studies, about 10% of people with MEN1 do not have a family history of the condition; they have a de novo (new) mutation in the MEN1 gene.

                                                                     Fig: Distribution of PNET's

Cardiovascular Endocrinology

Increase in worldwide prevalence of obesity-associated diabetes, dyslipidemia and hypertension makes it imperative that endocrinologists, cardiologists and others have a forum for new treatment and therapeutic developments. Patients with diabetes are at increased risk of developing a number of serious microvascular and macrovascular complications. Across all ages, the relative risk of developing cardiovascular disease (CVD) is ∼2 for patients with diabetes compared with the general population and CVD contributes significantly to the increased, albeit decreasing over time, mortality rate. Still, CVD accounts for up to 50% of deaths in patients with diabetes. The American Heart Association (AHA) predicts that by 2030, 40.5% of the US population will likely have some form of a CVD, and that the direct cost of treating CVDs will triple from $273 billion in 2010 to $818 billion in 2030; with indirect costs expected to increase from $172 billion to $276 billion in the same time period.

Pediatric Endocrinology

It is being acknowledged that the leading problem for infants and children was birth defects, prematurity/low birth weight, maternal complications of pregnancy, sudden infant death syndrome and respiratory distress syndrome. The rise in incidence of Type 2 diabetes in adolescents appears to parallel the very worrisome rise in excess body weight and obesity. There are a number of general pediatricians around the world. As per the records it is being acknowledged that globally 7.62% are registered pediatricians with specific specialty. USA is said to be one of the top most countries having a large number of pediatricians.  Global burden of pediatric mortality is increasing drastically every year. WHO estimates that 8.8 million deaths occur annually among infants and children < 5 years of age. 3.8 million in the first 30 days of life 36% of neonatal deaths due to infectious diseases. Nearly 9 million children under five die every year. Reflecting this imperative, we believe that professionally-oriented education in to cure pediatric diseases is essential in the training of clinicians and clinical academics who will provide the future leadership in this key area for global health.

Obesity and Metabolism

Obesity is a complex disease that is associated with a number of comorbidities, exaggerated mortality and reduced quality of life. With the rise in obesity among the older adult population, the cost burden is predicted to increase substantially: the combined medical costs associated with treatment of obesity-related diseases, cardiovascular diseases, and diabetes in the US alone have been estimated to increase by $48-66 billion/year from 2010 through 2030 according to Endocrine Facts and Figures. In a 2011 study of 300 Filipino-Americans, representative of the second largest Asian subgroup in the United States, a modified definition of MetS was used to take account of the ethnic-specific body structure: elevated waist circumference was outlined as 88 cm in women and 90 cm in men. In participants 35 to 75 years of age, 18.3% of the participants (21.1% of males and 15.7% of females) met the threshold for MetS. The prevalence of MetS was significantly less than the NHANES values for 2009-2010.

Diabetes Therapeutics and Diagnostics

27^th European Diabetes Congress, June 20-21, 2018 Rome, Italy; 29^th International Congress on Prevention of Diabetes and Complications, September 27-28, 2018 Berlin, Germany; International Conference on Diabetes and its Complications, May 28-29, 2018 Osaka, Japan; 2nd International Conference on Diabetes and Diabetic Nursing Care, September 28-29, 2018 Montreal, Canada; 2nd International Conference on Clinical Diabetes, Diabetic Medication &Treatment, September 27-29, 2018 Montreal, Canada; Diabetes Professional Care Conference and Exhibition, November 14-15, 2018 London, UK;  9th Welsh Conference of the Primary Care Diabetes Society, May 17, 2018 Cardiff, UK; Second Annual Qatar Diabetes, Endocrinology and Metabolic Conference, November 30 - December 2, 2017 Doha , Qatar; ENDO 2018, March 17-20, 2018 Chicago, USA; 2^nd International Diabetes Summit, March 9-10, 2018 Pune, India.

Endocrinology and Metabolism

13^th European Diabetes and Endocrinology Congress, November 26-27, 2018 Dublin, Ireland; 10th International Conference on Endocrinology & Endocrine Disorder, October 17-18, 2018 Las Vegas, USA; 12th International Conference on Endocrinology, Diabetes and Metabolism, October 01-02, 2018 Osaka, Japan; 11th World Congress on Endocrinology and Metabolic Disorders, September 3-4, 2018 Auckland, New Zealand; 11th Edition of International Conference on Endocrinology & Diabetelogy, August 9-10, 2018 Madrid, Spain; 33rd Annual Clinical Conference on Diabetes, May 24 - 27, 2018 Florida, USA; 5^th International Conference of Endocrinology and Diabetes, February 20-22, 2018 Riyadh, Saudi Arabia; The AACE 27th Annual Scientific & Clinical Congress, May 16-20, 2018 Boston, USA; 20th Annual Mayo Clinic Endocrine Update, January 30–February 2, 2017 Florida, USA; The Society for Endocrinology BES, November 6-8, 2017 Harrogate, UK.

Hormone Dependent Cancers

28th Euro Congress on Cancer Science & Therapy, August 09-10, 2018 Madrid, Spain; 36th World Cancer Conference October 11-13, 2018 Zurich, Switzerland; 13th European Diabetes and Endocrinology Congress, November 26-27, 2018 Dublin, Ireland; Functional and Clinical Insight in Hormone Dependent Cancers, August 6 - 11, 2017 Newry, US; Living Beyond Breast Cancer Conference, September 28-30, 2018 Philadelphia, USA; 5th World Congress on Cancer Research & Therapy, Oct 15 - 17, 2018, Las Vegas, USA; 17th International Congress on Hormonal Steroids and Hormones & Cancer, November  26-29 2018, Stellenbosch, South Africa.

Thyroid Disorders

2^nd International Conference on Thyroid and Pregnancy¸ September 03-04, 2018 Auckland, New Zealand; 13^th European Diabetes and Endocrinology Congress, November 26-27, 2018 Dublin, Ireland; 87th Annual Meeting of the American Thyroid Association, October 18-22, 2017Victoria, Canada; 20th International Conference on Thyroid Disorders and Therapy, March 27 - 28, 2018 Tokyo, Japan; 40th Annual Meeting of the European Thyroid Association, September, 09-12, 2017 Belgrade, Serbia; 41st Annual Meeting of the European Thyroid Association, September 15-18, 2018 Newcastle, England.

Related Endocrinology Societies | Diabetes Associations | Medical Associations

Society for Endocrinology, Endocrine Society, The American Association of Clinical Endocrinologists, European Society of Endocrinology, Endocrine Society of India, The Endocrine Society of Australia, The International Diabetes Federation (IDF), Diabetes UK, Primary Care Diabetes Society, The European Association for the Study of Diabetes (EASD), American Association of Diabetes Educators, International Society of Endocrinology, Pediatric Endocrine Society, Pediatric Endocrinology Nursing Society (PENS),  Belgian Endocrine Society, European Society for Paediatric Endocrinology, Philadelphia Endocrine Society, Irish Endocrine Society, British Society for Paediatric Endocrinology and Diabetes (BSPED), Welsh Endocrine and Diabetes Society, Endocrinology Society (KCLSU), American Diabetes Association, World Diabetes Foundation.